Using BCG Vaccine to Protect Health Care Workers in the COVID-19 Pandemic
- Conditions
- Non-specific Effects of VaccinesAbsenteeismMorbidityHeterologous ImmunityCOVID-19
- Interventions
- Biological: SalineBiological: BCG-Denmark
- Registration Number
- NCT04373291
- Lead Sponsor
- Bandim Health Project
- Brief Summary
Background: The COVID-19 pandemic challenges the available hospital capacity, and this will be augmented by absenteeism of healthcare workers (HCW). HCW are at high risk, currently HCW constitute 20% of all the COVID-19 cases in Denmark. Strategies to prevent absenteeism of HCW are urgently needed.
Bacille Calmette-Guérin (BCG) is a vaccine against tuberculosis, with protective non-specific effects against other infections; significant reductions in morbidity and mortality have been reported, and a plausible immunological mechanism has been identified.
We hypothesize that BCG vaccination can reduce HCW absenteeism during the COVID-19 pandemic.
Primary objective: To reduce absenteeism among HCW with direct patient contacts during the COVID-19 epidemic. Secondary objective: To reduce the number of HCW that are infected with SARS-CoV-2 during the COVID-19 epidemic and to reduce the number of hospital admissions amongst HCW with direct patient contacts during the COVID-19 epidemic.
Study design: A multi-center randomized placebo controlled trial. Study population: 1500 HCW with direct patient contacts; defined as nurses, physicians and other medical staff working at emergency rooms and wards where COVID-infected patients are treated.
Intervention: Participants will be randomized 1:1 to intradermal administration of a standard dose of BCG vaccine or placebo (saline).
Main study parameters/endpoints: Primary endpoint: Number of days of (unplanned) absenteeism for any reason. Secondary endpoints: Number of days of (unplanned) absenteeism because of documented COVID infection. Cumulative incidence of hospital admissions.
Risk for participants and impact: Based on previous experience and randomized controlled trials in adult and elderly individuals, the risks of BCG vaccination are considered low. The objective of this trial is to evaluate the potential beneficial effects of BCG vaccination through a lower work absenteeism rate of HCW and/or a mitigated clinical course of COVID infection.
- Detailed Description
BACKGROUND Health-care workers face an elevated risk of exposure to - and infection with - SARS-CoV-2. It is imperative to ensure the safety, health and fitness of hospital personnel in order to safeguard continuous patient care. Strategies to prevent COVID-19 or to mitigate its clinical consequences are urgently needed.
Bacillus Calmette-Guérin (BCG) was developed as a vaccine against tuberculosis, but our group has shown that it can protect against death from other infections, it has what we have called non-specific effects (NSEs).\[3\] In clinical studies, BCG vaccination was associated with less child mortality, mainly as a result of reduced neonatal sepsis and respiratory infections. In a WHO-commissioned meta-analysis, BCG was associated with 42% (95%CI: 24-55%) lower child mortality.
NSEs of BCG are not limited to children. An Indonesian trial has shown that consecutive BCG vaccination for 3 months reduced the incidence of acute upper tract respiratory infections by 80% (95%CI=22-95%).
It has been recently demonstrated that the non-specific beneficial effects of BCG vaccination are due to epigenetic and metabolic reprogramming of innate immune cells, a process termed 'trained immunity'. E.g. among humans receiving yellow fever vaccine virus, those who had received BCG had - compared to placebo treated subjects - lower viral load, and improved anti-viral responses.
We hypothesize that BCG vaccination may induce (partial) protection against susceptibility to and/or severity of COVID-19. This study will evaluate the efficacy of BCG to improve the clinical course of COVID-19 and to prevent absenteeism.
Given the immediate threat of the COVID-19 epidemic the trial has been designed as a pragmatic study with a highly feasible primary endpoint, that can be continuously measured. We have therefore chosen unplanned absenteeism from work as primary outcome, in line with an ongoing clinical trial of BCG in the Netherlands.
OBJECTIVES Primary objective: To reduce absenteeism among HCW with direct patient contacts during the COVID-19 epidemic. Secondary objective: To reduce the number of HCW that are infected with SARS-CoV-2 during the COVID-19 epidemic and to reduce the number of hospital admissions amongst HCW with direct patient contacts during the COVID-19 epidemic.
HYPOTHESIS BCG vaccination of HCW will reduce absenteeism by 20% over a period of 6 months.
METHODS
Study design and follow-up:
A multi-center randomized placebo-controlled trial.
STUDY POPULATION As the COVID-19 epidemic has already started in Denmark, our intention is to start as soon as possible. Recruitment of study participants will take place at participating hospitals, at departments were COVID-19 patients are treated and, thus, the risk of exposure to SARS-CoV-2 is high.
Participating hospitals Hospital PI Odense University Hospital Isik Somuncu Johansen Sygehus Lillebælt, Kolding Poul-Erik Kofoed Hvidovre Hospital Thomas Lars Benfield Nordsjællands Hospital Ellen Løkkegaard Aarhus University Hospital Christian Wejse Herning Hospital Lars Skov Dalgaard Sygehus Sønderjylland Christian B. Mogensen
TREATMENT OF SUBJECTS Participants will be randomized 1:1 to receiving one intradermal BCG vaccine or placebo. Participants that are randomized in the active arm will receive a BCG vaccine (BCG-Denmark, AJ Vaccines). Placebo will be 0.1 ml sterile 0.9 % NaCl, which has a similar color as the resuspended BCG vaccine.
STUDY PROCEDURES Day 0: Participants fill in a short questionnaire regarding baseline characteristics. A blood sample will be drawn for subsequent testing for SARS-CoV-2 antibodies. Participants will be randomised to BCG or placebo in a 1:1 ratio. Randomisation will be done centrally using the REDCap tool with stratification per hospital and by age groups (+/- 45 years of age) in blocks of 8.
Participants will be blinded to treatment. The physicians administering the BCG vaccine or placebo will not be blinded. In case of serious adverse events, the participant can be unblinded after consultation with the coordinating PI or sponsor.
The end of the trial is defined as whichever comes latest: the last patient's last registration in the online data collection, or 180 days.
Day 0 till end of trial (weekly): Short electronic questionnaire regarding work absenteeism, symptoms and side effects through REDCap. In case a participant reports acute respiratory symptoms indicating COVID-19, he or she will be tested depending on test availability.
End of trial: Participants are asked to fill in a final questionnaire. A blood sample will be drawn for subsequent testing for SARS-CoV-2 antibodies.
STATISTICAL ANALYSIS All analyses will be performed from the intention-to-treat principle. The primary endpoint will be analysed as counts per week (i.e. multiple observations per subject) using a Bayesian negative binomial regression. Similar regression models will be used for secondary endpoints: Number of days of unplanned absenteeism because of documented COVID; number of days of self-reported fever. Documented COVID, death for any reason, death due to documented COVID, cumulative incidence of Intensive Care Admission for any reason, cumulative incidence of Intensive Care Admission due to documented COVID, cumulative incidence of Hospital Admission for any reason, cumulative incidence of Hospital Admission due to documented COVID will be analysed in Cox proportional hazards models.
Participants will be followed until a new vaccine is given (but data will also be analyzed after receipt of a new vaccine type, to study potential interactions).
When applicable (i.e. in the event that one or more participants have died during the follow-up period) a competing events analysis will be performed in addition.
Interim analysis Every month, an interim analysis will be conducted by the independent statistician of the trial. The parallel Dutch trial will enable combined analysis that will strengthen the conclusions and increase the power to analyse the secondary outcomes and more rare outcomes as intensive hospitalization.
ETHICAL CONSIDERATIONS The study has ben approved by the Ethics Committee and by the Danish Medicines Agency.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1293
In order to be eligible to participate in this study, a subject must meet the following criteria:
- Adult (≥18 years);
- Hospital personnel caring for patients with COVID-19.
- Known allergy to (components of) the BCG vaccine or serious adverse events to prior BCG administration
- Known active or latent infection with Mycobacterium tuberculosis (M. tuberculosis) or other mycobacterial species
- Previous M. tuberculosis infection
- Previous confirmed COVID-19 infection
- Fever (>38 C) within the past 24 hours
- Suspicion of active viral or bacterial infection
- Pregnancy
- Severely immunocompromised subjects (This exclusion category comprises a) subjects with known infection by the human immunodeficiency virus (HIV-1); b) subjects with solid organ transplantation; c) subjects with bone marrow transplantation; d) subjects under chemotherapy; e) subjects with primary immunodeficiency; f) treatment with any anti-cytokine therapies. g) treatment with oral or intravenous steroids defined as daily doses of 10 mg prednisone or equivalent for longer than 3 months)
- Active solid or non-solid malignancy or lymphoma within the prior two years;
- Direct involvement in the design or the execution of the BCG-DENMARK-COVID study
- Employed to the hospital < 22 hours per week
- Not in possession of a smartphone/tablet.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Control Saline Placebo will be 0.1 ml sterile 0.9 % NaCl, which has a similar color as the resuspended BCG vaccine. BCG vaccine BCG-Denmark Participants that are randomized in the active arm will receive an adult 0.1 ml dose of BCG vaccine (BCG-Denmark, AJ Vaccines) in the skin covering the left upper deltoid muscle. Each 0.1 ml vaccine contains between 200000 to 800000 colony forming units of the live attenuated strain of Mycobacterium bovis (BCG), Danish strain 1331.
- Primary Outcome Measures
Name Time Method Number of days of unplanned absenteeism for any reason 6 months
- Secondary Outcome Measures
Name Time Method The cumulative incidence of documented COVID 6 months Number of days of (unplanned) absenteeism due to respiratory infections 6 months The cumulative incidence of Intensive Care Admission for any reason 6 months The number of days of self-reported acute respiratory symptoms 6 months Number of days of (unplanned) absenteeism due to infections 6 months The number of days of self-reported fever (≥38 °C) 6 months Cumulative incidence of infectious disease episodes, in particular respiratory infections 6 months The cumulative incidence of self-reported acute respiratory symptoms 6 months Cumulative incidence of all-cause and infectious hospital admissions, in particular respiratory infections 6 months The number of days of absenteeism, because of imposed quarantine as a result of exposure to SARS-CoV-2 6 months The number of days of unplanned absenteeism because of self-reported acute respiratory symptoms 6 months The cumulative incidence of death for any reason 6 months The cumulative incidence of death due to documented COVID 6 months The cumulative incidence of Intensive Care Admission due to documented COVID 6 months The cumulative incidence of Hospital Admission due to documented COVID 6 months The number of days of unplanned absenteeism, because of documented COVID 6 months The number of days of absenteeism, because of imposed quarantine as a result of having acute respiratory symptoms, fever or documented SARS- CoV-2 infection 6 months
Trial Locations
- Locations (1)
University of Southern Denmark
🇩🇰Odense, Region Of Southern Denmark, Denmark